Liver Disease Outcomes After Sustained Virological Response in Patients with Chronic Hepatitis C Infection Treated with Generic Direct-Acting Antivirals

Overview

Journal Am J Trop Med Hyg

Specialty Tropical Medicine

Date 2022 Feb 28

PMID 35226870

Authors

Ekram W Abd El-Wahab

Waleed M Abd Elgawad

Mohamed S Abdelaziz

Ashraf I Mikheal

Hanan Z Shatat

Affiliations

Soon will be listed here.

Abstract

The introduction of generic direct-acting antivirals (DAAs) in Egypt is associated with a superior cure rate of hepatitis C virus (HCV) infection. However, the course of progressive liver damage and developing liver related complications in patients with sustained virologic response (SVR) remain unclear. This study was designed to examine the long-term outcomes of generic DAA-induced virological cure in a real-life cohort of HCV patients with or without comorbid schistosomiasis. We prospectively enrolled a cohort of 506 recently cured HCV patients (437 Child-Pugh class A [Child-A] and 69 Child-Pugh class B [Child-B]). All patients were clinically evaluated at different time points during a 2-year follow-up (November 2018 to February 2021). Over the course of treatment and follow-up, 77 (15.2%) patients (42 [9.6%] Child-A and 35 [50.7%] Child-B) experienced complications at different time points. The overall mortality rate was approximately 1/1,000 person-years. The incidence of hepatic insufficiency was approximately 5.5/1,000 person-years, and that of de novo hepatocellular carcinoma (HCC) was approximately 8.3/1,000 person-years. A sustained improvement in liver indices up to 2 years of follow-up was observed. In the Cox regression model, pretreatment decompensated cirrhosis predicted the occurrence of adverse liver events and HCC after therapy. In conclusion, in HCV patients with advanced cirrhosis or coexisting hepatic schistosomiasis, generic DAA-induced SVR remains robust with favorable clinical outcomes although the risk of hepatocarcinogenesis cannot be eliminated. Surveillance of patients with treated HCV infection is an important aspect of postcure care for early detection and management of liver disease-related adverse events.

References

Singal A, Lim J, Kanwal F . AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review. Gastroenterology. 2019; 156(8):2149-2157. PMC: 6529246. DOI: 10.1053/j.gastro.2019.02.046. View

Negro F, Forton D, Craxi A, Sulkowski M, Feld J, Manns M . Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology. 2015; 149(6):1345-60. DOI: 10.1053/j.gastro.2015.08.035. View

Miyaki E, Imamura M, Hiraga N, Murakami E, Kawaoka T, Tsuge M . Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients. Hepatol Res. 2015; 46(8):758-64. DOI: 10.1111/hepr.12621. View

Nagaty A, Abd El-Wahab E . Real-life results of sofosbuvir based therapy in chronic hepatitis C -naïve and -experienced patients in Egypt. PLoS One. 2017; 12(10):e0184654. PMC: 5628811. DOI: 10.1371/journal.pone.0184654. View

Schuppan D, Afdhal N . Liver cirrhosis. Lancet. 2008; 371(9615):838-51. PMC: 2271178. DOI: 10.1016/S0140-6736(08)60383-9. View

Cheung M, Walker A, Hudson B, Verma S, McLauchlan J, Mutimer D . Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016; 65(4):741-747. DOI: 10.1016/j.jhep.2016.06.019. View

El-Tonsy M, Hussein H, Helal T, Tawfik R, Koriem K, Hussein H . Human Schistosomiasis mansoni associated with hepatocellular carcinoma in Egypt: current perspective. J Parasit Dis. 2016; 40(3):976-80. PMC: 4996231. DOI: 10.1007/s12639-014-0618-0. View

El-Serag H, Kanwal F, Richardson P, Kramer J . Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology. 2016; 64(1):130-7. PMC: 4917456. DOI: 10.1002/hep.28535. View

Knop V, Hoppe D, Welzel T, Vermehren J, Herrmann E, Vermehren A . Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy. J Viral Hepat. 2016; 23(12):994-1002. DOI: 10.1111/jvh.12578. View

10.

Yu M, Chang H, Chang S, Liaw Y, Lin S, Liu C . Role of reproductive factors in hepatocellular carcinoma: Impact on hepatitis B- and C-related risk. Hepatology. 2003; 38(6):1393-400. DOI: 10.1016/j.hep.2003.09.041. View

11.

Ziada D, El Sadany S, Soliman H, Abd-Elsalam S, Salama M, Hawash N . Prevalence of hepatocellular carcinoma in chronic hepatitis C patients in Mid Delta, Egypt: A single center study. J Egypt Natl Canc Inst. 2016; 28(4):257-262. DOI: 10.1016/j.jnci.2016.06.001. View

12.

Laursen T, Sandahl T, Kazankov K, George J, Gronbaek H . Liver-related effects of chronic hepatitis C antiviral treatment. World J Gastroenterol. 2020; 26(22):2931-2947. PMC: 7304101. DOI: 10.3748/wjg.v26.i22.2931. View

13.

Hassan M, Zaghloul A, El-Serag H, Soliman O, Patt Y, Chappell C . The role of hepatitis C in hepatocellular carcinoma: a case control study among Egyptian patients. J Clin Gastroenterol. 2001; 33(2):123-6. DOI: 10.1097/00004836-200108000-00006. View

14.

Van-Lume D, de Albuquerque M, de Souza A, Domingues A, Lopes E, de Morais C . Association between Schistosomiasis mansoni and hepatitis C: systematic review. Rev Saude Publica. 2013; 47(2):414-24. DOI: 10.1590/S0034-910.2013047004247. View

15.

Guarino M, Sessa A, Cossiga V, Morando F, Caporaso N, Morisco F . Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows. World J Gastroenterol. 2018; 24(24):2582-2595. PMC: 6021774. DOI: 10.3748/wjg.v24.i24.2582. View

16.

Pinero F, Mendizabal M, Ridruejo E, Herz Wolff F, Ameigeiras B, Anders M . Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma. Liver Int. 2019; 39(6):1033-1043. DOI: 10.1111/liv.14041. View

17.

. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017; 2(3):161-176. DOI: 10.1016/S2468-1253(16)30181-9. View

18.

. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J Hepatol. 2016; 65(4):734-740. DOI: 10.1016/j.jhep.2016.05.045. View

19.

El-Akel W, El-Sayed M, El Kassas M, El-Serafy M, Khairy M, Elsaeed K . National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care. J Viral Hepat. 2017; 24(4):262-267. DOI: 10.1111/jvh.12668. View

20.

Banerjee J . Portal hypertension. Med J Armed Forces India. 2014; 68(3):276-9. PMC: 3862884. DOI: 10.1016/j.mjafi.2012.04.008. View